Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Cash from Financing Activities (2019 - 2025)

Burning Rock Biotech has reported Cash from Financing Activities over the past 7 years, most recently at -$14000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 40.0% year-over-year to -$14000.0; the TTM value through Dec 2025 reached $255279.1, up 188.31%, while the annual FY2025 figure was $272000.0, 2820.0% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$14000.0 at Burning Rock Biotech, down from $279000.0 in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $279000.0 in Q2 2025 and troughed at -$12.5 million in Q4 2022.
  • A 5-year average of -$2.3 million and a median of -$375000.0 in 2022 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: crashed 1577.07% in 2023 and later skyrocketed 100.0% in 2024.
  • Year by year, Cash from Financing Activities stood at -$1.1 million in 2021, then tumbled by 1073.99% to -$12.5 million in 2022, then surged by 97.85% to -$269000.0 in 2023, then soared by 96.28% to -$10000.0 in 2024, then crashed by 40.0% to -$14000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for BNR at -$14000.0 in Q4 2025, $279000.0 in Q2 2025, and -$10000.0 in Q4 2024.